Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow m...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliva, Stefania, Troia, Rossella, D'Agostino, Mattia, Boccadoro, Mario, Gay, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277686/
https://www.ncbi.nlm.nih.gov/pubmed/30538704
http://dx.doi.org/10.3389/fimmu.2018.02749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277686/
https://www.ncbi.nlm.nih.gov/pubmed/30538704
http://dx.doi.org/10.3389/fimmu.2018.02749

Ejemplares similares